INFUSYSTEM HOLDINGS, INC Revenue from Contract with Customer, Including Assessed Tax
INFUSYSTEM HOLDINGS, INC (INFU) reported Revenue from Contract with Customer, Including Assessed Tax of $10.55 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-22.
Discontinued › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2019-03-22
- INFUSYSTEM HOLDINGS, INC revenue from contract with customer, including assessed tax for the quarter ending 2018-12-31 was $3.23M, a 6.23% increase year-over-year.
- INFUSYSTEM HOLDINGS, INC revenue from contract with customer, including assessed tax for the quarter ending 2018-09-30 was $2.90M, a 28.16% increase year-over-year.
- INFUSYSTEM HOLDINGS, INC revenue from contract with customer, including assessed tax for the quarter ending 2018-06-30 was $2.36M, a 8.74% increase year-over-year.
- INFUSYSTEM HOLDINGS, INC revenue from contract with customer, including assessed tax for the quarter ending 2018-03-31 was $2.06M, a 18.08% decline year-over-year.
- INFUSYSTEM HOLDINGS, INC revenue from contract with customer, including assessed tax for fiscal 2018 was $10.55M, a 5.62% increase from fiscal 2017.
- INFUSYSTEM HOLDINGS, INC revenue from contract with customer, including assessed tax for fiscal 2017 was $9.99M.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|
| 2018-12-31 | $3.23M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-22 | $6.13M derived: sum of 2 quarters · filed 2019-03-22 | $8.49M derived: sum of 3 quarters · filed 2019-03-22 | $10.55M 10-K · filed 2019-03-22 |
| 2018-09-30 | $2.90M 10-Q · filed 2018-11-13 | $5.27M derived: sum of 2 quarters · filed 2018-11-13 | $7.33M 10-Q · filed 2018-11-13 | $10.37M derived: sum of 4 quarters · filed 2019-03-22 |
| 2018-06-30 | $2.36M 10-Q · filed 2018-08-14 | $4.42M 10-Q · filed 2018-08-14 | $7.46M derived: sum of 3 quarters · filed 2019-03-22 | $9.73M derived: sum of 4 quarters · filed 2019-03-22 |
| 2018-03-31 | $2.06M 10-Q · filed 2018-05-14 | $5.10M derived: sum of 2 quarters · filed 2019-03-22 | $7.36M derived: sum of 3 quarters · filed 2019-03-22 | $9.54M derived: sum of 4 quarters · filed 2019-03-22 |
| 2017-12-31 | $3.04M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-22 | $5.30M derived: sum of 2 quarters · filed 2019-03-22 | $7.47M derived: sum of 3 quarters · filed 2019-03-22 | $9.99M 10-K · filed 2019-03-22 |
| 2017-09-30 | $2.27M 10-Q · filed 2018-11-13 | $4.44M derived: sum of 2 quarters · filed 2018-11-13 | $6.96M 10-Q · filed 2018-11-13 | |
| 2017-06-30 | $2.17M 10-Q · filed 2018-08-14 | $4.69M 10-Q · filed 2018-08-14 | ||
| 2017-03-31 | $2.52M 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Profound Medical Corp. (PROF) | $0.206B | -7.37 |